BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol 2019;10:1157. [PMID: 31258525 DOI: 10.3389/fimmu.2019.01157] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Reference Citation Analysis]
2 Luzzatto L. PNH phenotypes and their genesis. Br J Haematol 2020;189:802-5. [PMID: 32166737 DOI: 10.1111/bjh.16473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Yu J, Yuan X, Chen H, Chaturvedi S, Braunstein EM, Brodsky RA. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020;136:2080-9. [PMID: 32877502 DOI: 10.1182/blood.2020008248] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 40.0] [Reference Citation Analysis]
4 de Castro C, Grossi F, Weitz IC, Maciejewski J, Sharma V, Roman E, Brodsky RA, Tan L, Di Casoli C, El Mehdi D, Deschatelets P, Francois C. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol 2020;95:1334-43. [PMID: 33464651 DOI: 10.1002/ajh.25960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther 2020;20:227-37. [PMID: 32011183 DOI: 10.1080/14712598.2020.1725468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fattizzo B, Serpenti F, Giannotta JA, Barcellini W. Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. J Clin Med 2021;10:948. [PMID: 33804461 DOI: 10.3390/jcm10050948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 2021;21:1073-86. [PMID: 33513036 DOI: 10.1080/14712598.2021.1884223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
9 Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Front Immunol 2020;11:1460. [PMID: 32793201 DOI: 10.3389/fimmu.2020.01460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol 2021;8:e344-54. [PMID: 33765419 DOI: 10.1016/S2352-3026(21)00028-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Barratt J, Weitz I. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol 2021;12:712572. [PMID: 34566967 DOI: 10.3389/fimmu.2021.712572] [Reference Citation Analysis]
13 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
14 Röth A, Araten DJ, Larratt L, Kulasekararaj AG, Maciejewski JP, Wilson A, Gustovic P, Kanakura Y. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry. Eur J Haematol 2020;105:561-70. [PMID: 32640047 DOI: 10.1111/ejh.13485] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Markiewicz M, Drozd-Sokolowska J, Biecek P, Dzierzak-Mietla M, Boguradzki P, Staniak M, Piatkowska-Jakubas B, Piekarska A, Tormanowska M, Halaburda K, Ussowicz M, Waszczuk-Gajda A, Basak G, Bołkun L, Rybka J, Sadus-Wojciechowska M, Giebel S, Szmigielska-Kaplon A, Mendek-Czajkowska E, Warzybok K, Burdacki A, Dwilewicz-Trojaczek J. Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group. Biol Blood Marrow Transplant 2020;26:1833-9. [PMID: 32512214 DOI: 10.1016/j.bbmt.2020.05.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Sica M, Pellecchia A, De Angioletti M, Caocci G, Nannelli C, La Nasa G, Luzzatto L, Notaro R. Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH. Blood 2020;136:3082-5. [PMID: 32845970 DOI: 10.1182/blood.2020007780] [Reference Citation Analysis]
17 Patel BA, Giudice V, Young NS. Immunologic effects on the haematopoietic stem cell in marrow failure. Best Pract Res Clin Haematol 2021;34:101276. [PMID: 34404528 DOI: 10.1016/j.beha.2021.101276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 de Latour RP, Hosokawa K, Risitano AM. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Seminars in Hematology 2022. [DOI: 10.1053/j.seminhematol.2022.01.001] [Reference Citation Analysis]
20 Ruiz-Molina N, Parsons J, Müller M, Hoernstein SNW, Bohlender LL, Pumple S, Zipfel PF, Häffner K, Reski R, Decker EL. A synthetic protein as efficient multitarget regulator against complement over-activation. Commun Biol 2022;5:152. [PMID: 35194132 DOI: 10.1038/s42003-022-03094-5] [Reference Citation Analysis]
21 Gurnari C, Nautiyal I, Pagliuca S. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Ther Clin Risk Manag 2021;17:1343-51. [PMID: 34934322 DOI: 10.2147/TCRM.S273360] [Reference Citation Analysis]
22 Frieri C, Peffault de Latour R, Sicre De Fontbrune F. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Emerg Drugs 2022. [PMID: 35078384 DOI: 10.1080/14728214.2022.2031973] [Reference Citation Analysis]
23 Delvasto-Nuñez L, Jongerius I, Zeerleder S. It takes two to thrombosis: Hemolysis and complement. Blood Rev 2021;:100834. [PMID: 33985796 DOI: 10.1016/j.blre.2021.100834] [Reference Citation Analysis]
24 Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Tamura S, Hori Y, Hiroi T, Morimoto M, Yamashita Y, Mushino T, Sonoki T. Pegcetacoplan for refractory paroxysmal nocturnal haemoglobinuria associated with the C5 genetic variant. Br J Haematol 2021. [PMID: 34796912 DOI: 10.1111/bjh.17963] [Reference Citation Analysis]
26 Iolascon A, Rivella S, Anagnou NP, Camaschella C, Swinkels D, Muckenthaler MU, Porto G, Barcellini W, Andolfo I, Risitano AM, Kattamis A, Cappellini MD, Taher AT, De Franceschi L, Rees D, Russo R, Tamary H, Stauder R, Girelli D. The EHA Research Roadmap: Anemias. Hemasphere 2021;5:e607. [PMID: 34522846 DOI: 10.1097/HS9.0000000000000607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sultan EY, Rizk DE, Kenawy HI, Hassan R. A small fragment of factor B as a potential inhibitor of complement alternative pathway activity. Immunobiology 2021;226:152106. [PMID: 34147816 DOI: 10.1016/j.imbio.2021.152106] [Reference Citation Analysis]
28 Deghmane AE, Taha MK. Invasive Bacterial Infections in Subjects with Genetic and Acquired Susceptibility and Impacts on Recommendations for Vaccination: A Narrative Review. Microorganisms 2021;9:467. [PMID: 33668334 DOI: 10.3390/microorganisms9030467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhang L, Chen JY, Kerr C, Cobb BA, Maciejewski JP, Lin F. Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. Leukemia 2021;35:1176-87. [PMID: 32814838 DOI: 10.1038/s41375-020-1008-5] [Reference Citation Analysis]
30 Mannes M, Dopler A, Zolk O, Lang SJ, Halbgebauer R, Höchsmann B, Skerra A, Braun CK, Huber-Lang M, Schrezenmeier H, Schmidt CQ. Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity. Blood 2021;137:443-55. [PMID: 33507296 DOI: 10.1182/blood.2020005959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
31 Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021;137:1304-9. [PMID: 33512400 DOI: 10.1182/blood.2019003812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Debureaux PE, Kulasekararaj AG, Cacace F, Silva BGP, Calado RT, Barone F, Sicre de Fontbrune F, Prata PH, Soret J, Sica M, Notaro R, Scheinberg P, Mallikarjuna V, Gandhi S, Large J, Risitano AM, Peffault de Latour R, Frieri C; Severe Aplastic Anemia Working Party of the European Group for Bone Marrow Transplantation. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant 2021. [PMID: 34226670 DOI: 10.1038/s41409-021-01372-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Li L, Liu H, Wang H, Liu Z, Chen Y, Liu C, Zhao X, Li L, Wang H, Shao Z, Fu R. Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis. J Clin Lab Anal 2022;:e24239. [PMID: 35028973 DOI: 10.1002/jcla.24239] [Reference Citation Analysis]
35 Garlich J, Cinier M, Chevrel A, Perrocheau A, Eyerman DJ, Orme M, Kitten O, Scheibler L. Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation. Biomolecules 2022;12:432. [DOI: 10.3390/biom12030432] [Reference Citation Analysis]
36 Alashkar F, Saner FH, Vance C, Schmücker U, Herich-Terhürne D, Dührsen U, Köninger A, Röth A. Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation. Front Med (Lausanne) 2020;7:543372. [PMID: 33102497 DOI: 10.3389/fmed.2020.543372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Fattizzo B, Giannotta JA, Cecchi N, Barcellini W. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor. Am J Hematol 2021;96:E344-6. [PMID: 34057236 DOI: 10.1002/ajh.26262] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Risitano AM, Peffault de Latour R. How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol 2021. [PMID: 34355382 DOI: 10.1111/bjh.17753] [Reference Citation Analysis]
39 Fattizzo B, Kulasekararaj AG. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. BioDrugs 2020;34:149-58. [PMID: 31916226 DOI: 10.1007/s40259-019-00401-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
40 Hoy SM. Pegcetacoplan: First Approval. Drugs 2021;81:1423-30. [PMID: 34342834 DOI: 10.1007/s40265-021-01560-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Giannotta JA, Fattizzo B, Barcellini W. Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature. Front Oncol 2021;11:756589. [PMID: 34858830 DOI: 10.3389/fonc.2021.756589] [Reference Citation Analysis]
42 Cheng WY, Sarda SP, Mody-patel N, Krishnan S, Yenikomshian M, Kunzweiler C, Vu JD, Cheung HC, Duh MS. Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. CEOR 2022;Volume 14:357-69. [DOI: 10.2147/ceor.s346816] [Reference Citation Analysis]
43 Grunenwald A, Roumenina LT. The Benefits of Complement Measurements for the Clinical Practice. Methods Mol Biol 2021;2227:1-20. [PMID: 33847926 DOI: 10.1007/978-1-0716-1016-9_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Pedersen H, Jensen RK, Hansen AG, Gadeberg TAF, Thiel S, Laursen NS, Andersen GR. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. J Biol Chem 2020;295:8746-58. [PMID: 32376685 DOI: 10.1074/jbc.RA119.012339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
45 Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol 2019;114:341-52. [PMID: 31446305 DOI: 10.1016/j.molimm.2019.07.030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
46 Bhak RH, Mody-Patel N, Baver SB, Kunzweiler C, Yee CW, Sundaresan S, Swartz N, Duh MS, Krishnan S, Sarda SP. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin 2021;37:1913-23. [PMID: 34445916 DOI: 10.1080/03007995.2021.1971182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Mohebnasab M, Eriksson O, Persson B, Sandholm K, Mohlin C, Huber-Lang M, Keating BJ, Ekdahl KN, Nilsson B. Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics. Front Immunol 2019;10:2539. [PMID: 31787968 DOI: 10.3389/fimmu.2019.02539] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ter Avest M, Langemeijer SMC, Schols SEM, Burger DM, van de Kar NCAJ, Blijlevens NMA, Kievit W, Ter Heine R. The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs. Br J Clin Pharmacol 2021;87:3359-63. [PMID: 33512711 DOI: 10.1111/bcp.14748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood 2020;135:912-20. [PMID: 31978221 DOI: 10.1182/blood.2019003399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
50 Gerber GF, Yuan X, Yu J, Cher BAY, Braunstein EM, Chaturvedi S, Brodsky RA. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood 2021;137:3670-3. [PMID: 33945618 DOI: 10.1182/blood.2021011548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]